Exicure (XCUR) said its subsidiary, GPCR Therapeutics USA, dosed the 19th patient in an ongoing phase 2 clinical trial of a small molecule inhibitor in multiple myeloma patients undergoing autologous stem cell transplant.
The trial is expected to finish patient recruitment at the end of April.
The study is a multi-center trial evaluating the safety and efficacy of the CXCR4 inhibitor, GPC-100 (burixafor), and propranolol in combination with G-CSF, the company said late Monday.
It said the study's preliminary results are encouraging as 100% of patients achieved the primary endpoint of successful stem cell mobilization.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。